N/A
N=260
Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms
Aortic Aneurysm, Abdominal
Bottom Line
View on ClinicalTrials.gov: NCT00816062 ↗Enrolled (actual)
260
Serious AEs
50.0%
Results posted
Jan 2018
Primary outcome: Primary: Freedom From Aneurysm-related Mortality (ARM) — .97 Proportion of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Talent Abdominal Stent Graft (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medtronic Cardiovascular
- Primary completion
- Jul 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Freedom From Aneurysm-related Mortality (ARM) |
.97 | — |
Summary
The purpose of this study is to examine, through the endpoints established in this protocol, the long-term safety and effectiveness of the Talent Abdominal Stent Graft System, in a post-approval environment.
Eligibility Criteria
Inclusion Criteria
- Subject must have an abdominal aortic aneurysm, with or without iliac involvement.
- Iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories;
- A proximal aortic neck length of ≥ 10mm;
- Proximal aortic neck angulation ≤ 60°;
- Distal iliac artery fixation length of ≥ 15mm;
- An aortic neck diameter of 18-32mm and iliac artery diameters of 8-22mm; and
- Vessel morphology suitable for endovascular repair.
Exclusion Criteria
- Are less than 18 years of age
- Are pregnant or lactating
- Have a dominant patent inferior mesenteric artery and an occluded or stenotic celiac and/or superior mesenteric artery
- Have aneurysmal involvement or occlusion (surgically performed or naturally occurring) of the bilateral internal iliac arteries
- Have vessels and/or aneurysm dimensions that cannot accommodate the Talent Abdominal Stent Graft as per the indications in Section 3.
- Have no distal vascular bed (one vessel lower extremity run-off required)
- Have contraindications for use of contrast medium or anticoagulation drugs
- Have an uncorrectable coagulopathy
- Have an SVS/AAVS score greater than 2
- Have a mycotic aneurysm
- Have circumferential mural thrombus in the proximal aortic neck
- Have had a recent (within 3 months) myocardial infarction (MI), cerebral vascular accident (CVA), or major surgical intervention
- Have traumatic aortic injury
- Have leaking, pending rupture or ruptured aneurysms
- Have pseudoaneurysms resulting from previous graft placement
- Require a revision to previously placed endovascular stent grafts.
- Have genetic connective tissue disease (e.g., Marfan's or Ehlers-Danlos' Syndromes)
- Have concomitant thoracic aortic or thoracoabdominal aneurysms
- Are patients with active systemic infections
- Are patients who have a condition that threatens to infect the graft.
- Are patients with sensitivities or allergies to the device materials.
- Have access vessels (as determined by treating physician) that preclude safe insertion of the delivery system. NOTE: Iliac conduits may be used to ensure the safe insertion of the delivery system.
Data sourced from ClinicalTrials.gov (NCT00816062). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.